P-102 Real-world dosing of regorafenib and outcomes among patients with metastatic colorectal cancer: A retrospective analysis using US claims data
نویسندگان
چکیده
Regorafenib is an oral multikinase inhibitor approved for advanced mCRC, gastrointestinal stromal tumors, and hepatocellular carcinoma. The phase 2 regorafenib dose-optimization study (ReDOS; Bekaii-Saab TS, et al., 2019) demonstrated that patients could initiate at a dose of 80 mg/day then subsequently escalate their depending on tolerability without compromising efficacy. In March 2018, the ReDOS strategy was included as recommendation in US cancer guidelines. We conducted retrospective analysis using claims database to assess whether inclusion dose-escalation guidelines influenced use flexible dosing US. This with metastatic colorectal (mCRC) Optum Clinformatics who initiated between January 1, 2016, June 30, 2020. Patients were stratified based they before or after (March 31, 2018) number tablets taken first 28-day treatment cycle (< 84 ≥84 hereby defined standard group, respectively). proportion received dose, cycle, third regorafenib, mean cycles analyzed. A total 703 during period, whom 310 (44%) prior to, 393 (56%) after, After guidelines, increased from 21% (n=66/310) 45% (n=178/393), decreased 79% (n=244/310) 55% (n=215/393), 36% (n=113/310) 46% (n=179/393), 2.64 (standard deviation [SD] 2.93) 3.20 (SD 3.11). An uptake (24%) observed Similarly, both reached by 10% 21%, respectively. These results suggest clinicians may have adopted clinical practice, which improve duration treatment.
منابع مشابه
Combination chemotherapy with Regorafenib in metastatic colorectal cancer treatment: A single center, retrospective study
BACKGROUND Regorafenib has been demonstrated as effective in refractory metastatic colorectal cancer. Combination use with chemotherapy has not been reported. We examined the efficacy and safety of adding chemotherapy to Regorafenib for the treatment of metastatic colorectal cancer(mCRC) patients. METHODS We recruited mCRC patients at our institute who received either regorafenib monotherapy ...
متن کاملRegorafenib in metastatic colorectal cancer: optimal dosing and patient selection recommendations.
متن کامل
Off-target effects and clinical outcome in metastatic colorectal cancer patients receiving regorafenib: The TRIBUTE analysis
Regorafenib is an orally administered multikinase inhibitor indicated for the treatment of heavily pretreated metastatic colorectal cancer patients with good performance status, albeit less than 50% treated patients achieve disease stabilisation or better at the first radiological evaluation. In addition to that a particularly broad spectrum of toxicities (experienced as G3 or more NCI CTCAE gr...
متن کاملEfficacy, Safety and Cost of Regorafenib in Patients with Metastatic Colorectal Cancer in French Clinical Practice
BACKGROUND Regorafenib is an orally administered multikinase inhibitor that has been approved for patients with chemotherapy-refractory metastatic colorectal cancer (mCRC). Even though regorafenib significantly improved survival in two international phase 3 trials (CORRECT and CONCUR), a high rate of treatment-related toxic effects and dose modifications were observed with a modest benefit. The...
متن کامل“How should we treat older patients with Metastatic Colorectal Cancer, A Review”
Nearly 50 % of newly diagnosed colorectal cancer, affect people over 70 years of age. Inclusion of older patients in clinical trials has been extremely rare. As a result, there is debate on how to manage these patients because it is still unclear how to balance the therapeutic advantages and toxicities. For patients who do not have comorbid conditions, with performance status (P.S.) 0–1, treatm...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Annals of Oncology
سال: 2022
ISSN: ['0923-7534', '1569-8041']
DOI: https://doi.org/10.1016/j.annonc.2022.04.192